Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of... December 6, 2022 FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... January 5, 2021 Stem cell research: meet the scientist growing ‘mini guts’ in her... April 8, 2022 Load more HOT NEWS Immunotherapy’s Skin Side Effects: Are Microbes to Blame? ΠΟΝΟΣ Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... EMA Recommends Extension of Indications for Pirtobrutinib
